Health-Related Quality of Life in Patients with Metastatic Basal Cell Carcinoma Treated with Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial

Main Article Content

Karl D Lewis
Timothy J Inocencio
Ruben GW Quek
Patrick R LaFontaine
Zeynep Eroglu
Anne Lynn S Chang
Cristina Ivanescu
Alexander J Stratigos
Ketty Peris
Aleksandar Sekulic
Matthew G Fury
Chieh-I Chen


quality of life, cemiplimab, metastatic basal cell carcinoma, open-label, Phase 2


1. Migden MR et al. Cancer Treat Rev. 2018;64:1–10.

2. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. Libtayo® [cemiplimab-rwlc injection for intravenous use] prescribing information. Revised November 2022. Available at: Accessed January 30, 2023.

3. Lewis K et al. Cancer Res. 2022;82(12 suppl):CT165.

4. Stratigos AJ et al. J Clin Oncol. 2021;39(15 suppl):9566.

5. Stratigos AJ et al. Lancet Oncol. 2021;22:848–857.

6. Aaronson NK et al. J Natl Cancer Inst. 1993;85:365–376.

7. Chren MM et al. J Cutan Med Surg. 2001;5:105–110.

8. Osoba D et al. J Clin Oncol. 1998;16:139–144.

9. Hansson J et al. Eur J Dermatol. 2018;28:775–783.

10. Scott NW et al. EORTC QLQ-C30 Reference Values. Available at: Accessed January 30, 2023.

Most read articles by the same author(s)

1 2 > >>